Pretreatment Tumor NECTIN4 RNA Expression Is Associated with First-line Enfortumab Vedotin Plus Pembrolizumab Efficacy in Metastatic Urothelial Cancer.

Byuri Angela Cho¹, Curtis J Perry², Seong-Keun Yoo³, Jacob Mercer⁴, Christina Thai⁴, Guru Sonpavde⁵, Paul A Fields⁴, Alan Tan⁴, Daniel P Petrylak⁶, Matthew D Galsky⁷

¹Genomic Medicine Institute, Medical Research Center, Seoul National University, Seoul, Republic of Korea.

²Department of Internal Medicine, Yale University, New Haven, CT, USA.

³Samsung Precision Genome Medicine Institute, Samsung Medical Center, Seoul, Republic of Korea.

⁴Tempus AI, Inc., Chicago, IL, USA.

⁵AdventHealth Cancer Institute and the University of Central Florida, Orlando, FL, USA.

⁶Smilow Cancer Hospital, Yale New Haven Health, New Haven, CT, USA.

⁷Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: matthew.galsky@mssm.edu.

PubMed DOI

Abstract

Enfortumab vedotin (EV) + pembrolizumab (P; EV + P) is the preferred first-line standard-of-care treatment for metastatic urothelial carcinoma (mUC), yet predictive biomarkers remain lacking. We retrospectively investigated whether tumor NECTIN4 RNA expression and tumor mutational burden (TMB) are associated with outcomes in a real-world mUC cohort receiving first-line EV + P (N = 322). NECTIN4-hi…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.